Bortezomib-induced peripheral neuropathy: Facts and genes

The Lancet Oncology

Volumn 12, Issue 2, 2011, Pages 120-121

  Cavaletti, Guido ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; VINCRISTINE;

DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; LETTER; MYELOMA; NEUROPATHIC PAIN; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; GENE EXPRESSION PROFILING; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; SEVERITY OF ILLNESS INDEX;

EID: 79251484332     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70020-1     Document Type: Letter

References (5)

1. Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010, 11:1057-1065.
2. Argyriou AA, Iconomou G, Kalofonos HP Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008, 112:1593-1599.
3. Cavaletti G Chemotherapy-induced peripheral neurotoxicity: how can we improve knowledge?. Lancet Oncol 2009, 10:539-540.
4. Hughes R NCI-CTC vs TNS: which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy?. Nat Clin Pract Neurol 2008, 4:68-69.
5. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998, 9:739-744.